A number of countries including the United States and the United Kingdom are moving to make a third dose of COVID-19 vaccine available to people who are immunocompromised.
Sep 1, 2021
0
4
Israel is pressing ahead with its aggressive campaign of offering coronavirus boosters to almost anyone over 12 and says its approach was further vindicated by a U.S. decision to give the shots to older patients or those ...
Sep 25, 2021
0
11
U.K. government advisers have recommended against giving a fourth dose of COVID-19 vaccine to nursing home residents and people over 80 because data shows that a third shot offers lasting protection against admission to the ...
Jan 8, 2022
0
10
Spain is making available a fourth COVID-19 vaccine dose to vulnerable citizens, including those with cancer, who have had a transplant or are receiving dialysis, the health ministry said Thursday.
Jan 13, 2022
0
3
Millions of Americans are now eligible to receive a Pfizer booster shot to help increase their protection against the worst effects of the coronavirus.
Sep 24, 2021
0
4
Australia has just expanded access to a second COVID booster to everyone 30 years and over, while recommending it only for people 50 and over. That means it's up to people aged 30–49 years to decide whether they would like ...
Jul 7, 2022
0
11
COVID cases in Australia appear to be on the increase, most likely due to community transmission of the omicron variant XBB. Meanwhile, a second omicron variant—BQ.1—is now being recorded in Australia.
Nov 11, 2022
0
6
(HealthDay)—Receipt of a third COVID-19 mRNA vaccine dose is associated with increased vaccine effectiveness against COVID-19 hospitalization, according to research published in the Jan. 28 issue of the U.S. Centers for ...
Jan 28, 2022
0
4
Three doses of either the same vaccine or a combination of different vaccine types work comparably well in preventing COVID-19 infections, even against different variants, finds a study published by The BMJ today.
May 31, 2022
0
83
A booster shot of the anti-COVID-19 vaccine developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection, according to trial data published by the makers on Thursday.
Oct 21, 2021
0
2
